! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, and clinical scientists representing all biomedical disciplines. YCC arms these investigators with a suite of enabling cores and powerful collaborative opportunities and resources. Through intra- and inter-programmatic collaboration, the overarching goals of YCC are to understand and prevent cancer, detect cancer early, and manage cancer treatment more accurately and effectively. The seven Research Programs are the heart of YCC, and each program is led by a basic scientist in partnership with a clinical/translational scientist to foster transdisciplinary research and the advancement of Yale science from the bench to the clinic. In addition, YCC supports and manages Shared Resources that provide unique expertise and enabling technologies that enrich the scope and expedite progress of each Research Program. YCC infrastructure further enables ground-breaking clinical trials that capitalize on Yale science and incorporate novel designs and biomarker assessments to optimize patient selection, define treatment resistance, and inform new therapeutic approaches. Overall cancer funding (direct costs) has increased 51% from $58.2M in 2012 to $88M in 2017, including an increase from $17.8M to $23.5M in NCI funding (direct costs). YCC holds two NCI SPORE grants, a UM1, U10, multiple P01s, numerous multi- investigator R01 grants, and leadership in two SU2C Dream Team awards. Additionally, during the current funding cycle, YCC leveraged $5.9M, reflecting CCSG Developmental Funds and institutional support, to advance new research and collaborations, resulting in $55.6M in new extramural funding - a 9-fold return on investment. During the same period, accrual to interventional treatment trials increased 82%, from 471 to 859, and accruals to early-phase treatment trials (pilot, I, I-II) increased three-fold, now representing 44% of total treatment accruals. No less important, YCC has expanded and invested in initiatives and research that seeks to impact cancer inequities and the needs of our catchment area at an individual, institutional, and policy level. Over the next five years, YCC will continue to develop initiatives and resources to foster innovation, collaboration, excellence and synergy to maximize the impact of Yale?s talent and expertise on the understanding, prevention and treatment of cancer.!

Public Health Relevance

The overarching mission of Yale Cancer Center (YCC) is to understand and prevent cancer, detect cancer early, and manage more accurately and effectively cancer treatment. YCC is committed to fulfilling these goals by supporting collaborative research and education activities aimed at delivering the highest quality patient- centered care, achieving breakthrough discoveries, and training future leaders in cancer science and medicine. !

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Internal Medicine/Medicine
Schools of Medicine
New Haven
United States
Zip Code
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 675 publications